The company told investors in May that it was "seeing encouraging traction" from the site, adding that "early data shows strong demand concentrated in GLP-1 therapies
CHAOS trial demonstrated that -tocopherol is able to reduce the incidence of myocardial infarction, however, failed to reduce the mortality in cardiovascular diseases (Stephens et al
Seek advice if you experience: Severe or persistent stomach pain or cramping Repeated vomiting or difficulty keeping fluids down Unexplained or rapid weight loss Fever, chills, or signs of dehydration Blood in stools or black, tar-like stools Symptoms that continue for several weeks without improvement These symptoms may suggest an underlying digestive issue that requires further assessment
Taken together, the figure highlights a key mechanistic principle underlying the therapeutic rationale for multi-agonist strategies: while GLP-1R monotherapy achieves meaningful metabolic and hepatic benefits exclusively through indirect, systemic pathways, the addition of GIPR and - most importantly - GCGR co-agonism introduces complementary and increasingly direct hepatic mechanisms, providing the pharmacological basis for the superior efficacy observed with dual and triple agonists in MASLD/MASH
Thus, sequence of neuronal damage may be bilirubin-induced oxidative stress and mitochondrial alterations
